{"id":"f7e04e6b-ca47-4b0f-998c-0c54bcca18a1","slug":"timing-of-chronic-subdural-hematoma-treatment-affects-middle-meningeal-artery-embolization-outcome","title":"Timing of chronic subdural hematoma treatment affects middle meningeal artery embolization outcome","authors":["Naoya Imai","Takayuki Kato","Yohei Ito","Ryo Morishima","Tatsuki Aki","Shin-ichi Shirakami"],"abstract":"Background: Chronic subdural hematoma (CSDH) is a condition that tends to recur frequently. Although middle meningeal artery embolization (MMAE) is an effective CSDH treatment, there is currently no consensus regarding the optimal timing for embolization. Methods: In this single-center and retrospective study, we reviewed 72 cases with 1st-time recurrent CSDH from January 2018 to July 2023 and identified those treated with MMAE to examine its effect and the impact of differences in the timing of treatment. Results: Of the 72 cases with CSDH recurrence for the 1st time (mean age: 80.4 ± 9.7 years; men: 62 [86.1%]; mean first recurrence interval: 33 ± 24 days), 27 (37.5%) experienced a second recurrence. The mean first recurrence interval was shorter in cases with a second recurrence compared to cured cases: 24.3 ± 18.6 versus 38.3 ± 25.6 days, respectively (P = 0.005). MMAE was performed in 17 (23.6%) cases (mean age: 82 ± 6.2 years; men: 14 [82.4%]). The mean time from initial surgical treatment to embolization was 52.4 ± 35.4 days, and the mean recurrence interval before MMAE was 24.9 ± 19.6 days. Six cases (35.3%) experienced post-embolization recurrence and required surgical treatment. The mean recurrence interval before MMAE was shorter in cases with recurrence after MMAE (15 ± 6.4 vs. 30 ± 22.1 days, P = 0.023). The time from initial surgical treatment to embolization was significantly shorter: 31.3 ± 12.8 versus 63.9 ± 38.9 days (P = 0.039). Conclusion: Cases with a short first recurrence interval were more likely to experience a second recurrence. Repeated recurrences within a short time increased the likelihood of post-embolization recurrence. MMAE performed early following the initial surgical treatment increased the recurrence risk.","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/f7e04e6b-ca47-4b0f-998c-0c54bcca18a1/featured/hero-1781559464241.png","publishDate":"2024-06-21T00:00:00.000Z","doi":"10.25259/SNI_293_2024","categories":["General Neurosurgery","Original Article"],"fullTextUrl":"https://surgicalneurologyint.com/api/articles/f7e04e6b-ca47-4b0f-998c-0c54bcca18a1/pdf"}